Polymyxin-like Lipopeptide Antibiotics Of The Future
Funder
National Health and Medical Research Council
Funding Amount
$335,323.00
Summary
Polymyxins are now being clinically used as the ‘last-line’ therapy for infections caused by multidrug-resistant Gram-negative ‘superbugs’. For the first time our novel approach will interface chemistry and biology of the polymyxins with the purpose of creating a new generation of safer and more efficacious polymyxin antibiotics.